Physician profile
Yan Bai
NPI 1558612804
$8,066.15
in general payments reported to CMS, 2019-2025
34 companies · $1,877 in 2025
The $1,877 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $897 · 2023: $1,953 · 2024: $3,219 · 2025: $1,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,049.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,134.75 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $773.99 | 2021-2025 | |
| Glaxosmithkline, LLC. | $769.03 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Almatica Pharma LLC | $679.74 | 2022-2025 | Loreev Xr, Gralise, Teriparatide |
| Novo Nordisk INC | $558.17 | 2023-2025 | Ozempic, Rybelsus |
| Amgen INC. | $466.00 | 2021-2025 | Repatha, Repatha, Otezla |
| Oyster Point Pharma, INC. | $461.57 | 2023-2025 | Tyrvaya |
| Lilly USA, LLC | $409.89 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $356.08 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $273.27 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $262.53 | 2024 | Rezdiffra |
| Gilead Sciences, INC. | $242.72 | 2023 | Vemlidy |
| Ardelyx, INC. | $199.14 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $196.92 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.05 | 2023-2025 | Xifaxan, Trulance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $148.09 | 2022-2025 | Zoryve, Seglentis, Livalo |
| Lundbeck LLC | $124.96 | 2024-2025 | Rexulti |
| Vivus LLC | $108.57 | 2024-2025 | Pancreaze |
| Abbvie INC. | $86.87 | 2023-2025 | |
| Amarin Pharma, INC. | $83.58 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $79.78 | 2024 | |
| Pfizer INC. | $64.13 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $47.92 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $44.69 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $44.60 | 2025 | Gemtesa |
| Radius Health, INC. | $42.59 | 2023 | Tymlos |
| Otsuka America Pharmaceutical, INC. | $42.29 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.78 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $30.04 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $28.35 | 2025 | Korlym |
| Emd Serono, INC. | $23.73 | 2024 | |
| Redhill Biopharma INC. | $23.28 | 2023 | Talicia |
| Ibsa Pharma INC. | $20.61 | 2023 | Tirosint, Licart |
| Dexcom, INC. | $19.44 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Bai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.